What is Zacks Research’s Estimate for DNLI FY2027 Earnings?

Denali Therapeutics Inc. (NASDAQ:DNLI) – Research analysts at Zacks Research issued their FY2027 EPS estimates for Denali Therapeutics in a research note issued on Thursday, March 13th. Zacks Research analyst A. Chakraborty anticipates that the company will post earnings per share of ($2.25) for the year. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.08.

DNLI has been the subject of a number of other research reports. JPMorgan Chase & Co. decreased their target price on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research report on Tuesday, January 7th. Robert W. Baird began coverage on Denali Therapeutics in a report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 target price on the stock. Baird R W raised Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 7th. Morgan Stanley started coverage on Denali Therapeutics in a research note on Friday, March 7th. They issued an “overweight” rating and a $33.00 price objective on the stock. Finally, William Blair reaffirmed an “outperform” rating on shares of Denali Therapeutics in a research note on Friday, February 28th. Two research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.20.

Denali Therapeutics Stock Performance

NASDAQ:DNLI opened at $15.44 on Monday. Denali Therapeutics has a 1 year low of $14.01 and a 1 year high of $33.33. The business has a fifty day moving average of $20.17 and a 200-day moving average of $23.90. The stock has a market cap of $2.24 billion, a price-to-earnings ratio of -5.59 and a beta of 1.46.

Hedge Funds Weigh In On Denali Therapeutics

A number of large investors have recently made changes to their positions in DNLI. Rhumbline Advisers increased its stake in shares of Denali Therapeutics by 0.3% in the fourth quarter. Rhumbline Advisers now owns 190,390 shares of the company’s stock worth $3,880,000 after acquiring an additional 497 shares during the last quarter. Assetmark Inc. grew its stake in Denali Therapeutics by 18.0% in the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after purchasing an additional 580 shares in the last quarter. PNC Financial Services Group Inc. increased its position in Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock worth $77,000 after purchasing an additional 885 shares during the last quarter. Sterling Capital Management LLC raised its stake in shares of Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock worth $36,000 after purchasing an additional 1,516 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Denali Therapeutics by 0.8% during the 4th quarter. The Manufacturers Life Insurance Company now owns 208,521 shares of the company’s stock valued at $4,250,000 after buying an additional 1,702 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 29,266 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $591,758.52. Following the sale, the chief executive officer now directly owns 260,721 shares of the company’s stock, valued at $5,271,778.62. The trade was a 10.09 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Vicki L. Sato sold 3,080 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares of the company’s stock, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 47,940 shares of company stock valued at $973,442. 7.90% of the stock is currently owned by corporate insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.